Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.

Current status and perspectives in immunotherapy for metastatic melanoma / R. Marconcini, F. Spagnolo, L.S. Stucci, S. Ribero, E. Marra, F.D. de Rosa, V. Picasso, L.D. di Guardo, C. Cimminiello, S. Cavalieri, L. Orgiano, E. Tanda, L. Spano, A. Falcone, P. Queirolo, G. Palmieri, I. Stanganelli, M. Mandala, P. Quaglino, G. Botti, C. Caraco, V.C. Sileni, A.M. di Giacomo. - In: ONCOTARGET. - ISSN 1949-2553. - 9:15(2018), pp. 12452-12470. [10.18632/oncotarget.23746]

Current status and perspectives in immunotherapy for metastatic melanoma

S. Cavalieri;G. Palmieri;
2018

Abstract

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.
Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
oncotarget-v9i15-23746.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.83 MB
Formato Adobe PDF
1.83 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/905299
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 56
  • ???jsp.display-item.citation.isi??? ND
social impact